Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence.

Twice-daily moisturization is recommended by international guidelines as the bedrock of the management of atopic dermatitis (AD). Moisturizers should be selected based on proven clinical effectiveness in improving the skin barrier and improving the symptoms of AD. We searched the PubMed database for clinical trials assessing daily moisturization for the treatment of AD published between 2006 and 2019. Studies had to assess the efficacy of commercially available moisturizers using objective measures of corneometry, transepidermal water loss, or incidence of flare as endpoints, and treatments had to be currently available to patients. Clinical studies showed that moisturization (typically twice daily) significantly improved the skin barrier in adults and children with AD. Longer-term flare studies showed that daily moisturization reduced the incidence of flares and extended the time between flares. Proactive moisturization of infants at high risk of developing AD may reduce its manifestation. Therapeutic moisturizers for AD are specifically formulated with ingredients that target symptoms of AD, such as itch, inflammation, or compromised skin barrier. The US FDA requires that any moisturizer available in the USA and claiming to treat AD must contain colloidal oatmeal. Healthcare providers can maximize compliance and outcomes by educating patients on the benefits of liberally applying a therapeutic moisturizer twice daily to support the skin barrier and help reduce the incidence of flares. Specific recommendations should be for clinically tested moisturizers evaluated using objective, validated skin assessments.

Key Points

Introduction

Atopic dermatitis (AD) affects more than 18 million people in the USA [1]. Daily moisturization is the standard or “bedrock” of the basic disease management of AD [2, 3]. A comprehensive review of 14 independent published guidelines from across the globe (USA, UK, Europe, Japan, Korea, Singapore, Canada, South Africa, and individual European countries) revealed that daily moisturization was a consistent recommendation for AD management [4].

Guidelines recommend liberal application of moisturizer on lesional and nonlesional skin, ideally at least twice daily [4, 5]. In mild AD, a daily moisturizer may be the primary therapy but should also be continued as complementary therapy when treating moderate and severe disease [2, 3]. Reviews of this subject area have revealed similar recommendations [6-9]; however, these studies were mainly focused on the active ingredients applied or on less recent or selected studies, respectively.

The objective of this review was to evaluate and present the clinical data behind commercially available products in a succinct guide based on accepted scientific criteria, so that healthcare providers can make informed choices and recommendations to their patients for proven therapies.

Clinical Evidence That Moisturizers Can Improve Outcomes in Atopic Dermatitis (AD)

AD is characterized by compromised epidermal barrier integrity. Even the skin of a patient that is not flaring is compromised and has imperfect barrier function [10-14]. The purpose of daily moisturization is to repair and support the skin barrier, thereby reducing the risk of flares.

To evaluate the clinical efficacy of daily emollient therapy for improving the skin barrier of patients with AD, we conducted a review of clinical studies of moisturizers in AD treatment. We searched the PubMed database using the terms “atopic dermatitis” OR “atopic” OR “eczema” plus all combinations of “barrier,” “topical,” “steroid-free,” “moisturizer,” and “moisturization.” Reference lists were also reviewed, particularly those from a 2017 Cochrane database review [15] and a 2018 evidence-based review [9].

Clinical studies were selected to provide practicing dermatologists with relevant data on commercially available, clinically tested nonprescription moisturizers to enable them to make informed recommendations. Clinical trials were selected that included study subjects with a diagnosis of AD or who were at high risk for developing AD. Studies had to include objective, biophysical barrier measures of transepidermal water loss (TEWL) and/or corneometry (see Table 1) to assess their efficacy at improving the skin barrier. If validated clinical assessment scales were included in these studies, these results were also reviewed. In addition, we selected studies that examined the ability of daily moisturization to prevent disease onset (primary prevention) or AD flares (secondary prevention).

Table 1

Validated skin assessments commonly used in atopic dermatitis studies

Assessment	Assessment type	Description	Outcome
TEWL	Biophysical	Tewa Meter or similar device directly measures water loss from skin in g/m2/h	High values indicate defective barrier function; low values indicate tight barrier
Corneometry	Biophysical	Corneometer indirectly measures hydration by detecting capacitance changes due to water content in skin	High values indicate greater hydration; low values indicate dry skin
SCORAD	Clinical	Measure of signsa and symptomsb on scale of 0–103	High score indicates more severe clinical phenotype
EASI	Clinical	Measure of signsc on scale of 0–72	High score indicates more severe clinical phenotype
ADSI	Clinical	Measure of signs and symptomsd on scale of 0–15	High score indicates more severe clinical phenotype

ADSI Atopic Dermatitis Severity Index, EASI Eczema Area and Severity Index, SCORAD Scoring Atopic Dermatitis, TEWL transepidermal water loss

aRedness, swelling, oozing/crusting, excoriation, lichenification, dryness

bItching, sleeplessness

cErythema, edema/papulation, excoriation, lichenification

dErythema, pruritus, exudation, excoriation, lichenification

Studies that only assessed clinical symptoms or measured moisturization at 24 h after a single application were excluded, as were studies reporting on medical devices, products requiring a prescription (e.g., Atopiclair, EpiCeram), and studies testing single ingredients such as glycerol [16]. Studies were limited to those published from January 2006 until December 2019 that tested products that are currently on the market.

Summary of Clinical Study Findings

The literature search identified 13 different nonprescription and cosmetic products tested in pediatric populations and 11 tested in adult populations with AD. Overall, clinical studies demonstrated that daily moisturization increased skin hydration and decreased TEWL in both children and adults (Table 2). While the majority of studies tested twice-daily application, once-daily treatment also showed skin barrier improvements. The analyses were mostly comparisons with baseline values, demonstrating improvements over time. Side-by-side comparisons (split-body) of treatment versus no treatment also indicated that, in almost all cases, moisturization improved skin barrier integrity compared with no treatment.

Table 2

Clinical studies of moisturizers for the treatment of atopic dermatitis

Product	Patient (n), age, AD conditiona	Study design	Treatment regimen	Endpoints	Comparators	Statistical comparisons		Concomitant medications	References
					Vehicle, active, or untreated	Treatment vs. pretreatment	Treatment vs. vehicle, untreated control, or active comparator
Skin barrier: Pediatric studies
Atobarrier Creamb	30 pts, 5–19 y, mild AD	OL	QD 4 wk entire body; TID to affected areas	SCORAD, TEWL, corneometry	None	↓ SCORAD (p < 0.0001); ↑ hydration (p < 0.0001); TEWL NS	NA	No	Na et al. [17]
Avene Xeracalm balmc	54 pts 1–4 y, mild AD, no flares	2-arm RCT, OL	BID face and body + QD cleansing gel 28 d	SCORAD, TEWL	Cleansing gel alone	↓ SCORAD (p < 0.001); ↓ TEWL (p = 0.06)	↓ SCORAD (p < 0.001), ↓ TEWL (p < 0.0001) vs. cleansing gel alone	No	Bianchi et al. [18]
Cetaphil Restoraderm lotion and wash regimec	24 pts, mean age 13.9 y	OL	QD wash; BID lotion 2 wk	SCORAD, corneometry, TEWL	None	↓ SCORAD (p = 0.039); ↑ Corneometry (p = 0.021); TEWL NS	NA	Usual TCS as necessary ~ 50% use	Hon et al. [19]
Cetaphil Restoraderm Moisturizerc	42 pts, > 3 y, mild–mod AD	RCT, evaluator-blinded, split-side	BID to half of body 4 wk; other half untreated	Corneometry, EASI	Untreated	↑ Hydration to both sides of body (p < 0.05); ↓ EASI on both sides body (p < 0.05)	↑ Hydration (p < 0.05), ↓ EASI (p < 0.05) at d 7, 14, 21 vs. untreated	TCS to all affected areas on both sides of body	Simpson et al. [20]
Cetaphil Restoraderm Moisturizer plus body washc	56 pts, 3–36 mo, AD	OL	At least QD to general skin surface and as needed to localized areas, 4 wk	TEWL, corneometry	None	↓ TEWL (p < 0.01); ↑ Hydration (p < 0.0001)	NA	Low potency TCS allowed	Simpson et al. [21]
Curel Moisture Creamb	33 pts, 5–18 y, AD	OL	BID 4 wk to forearms and affected areas	Corneometry, TEWL, SCORAD	None	↑ Hydration (p = 0.016); TEWL NS; SCORAD NS; ↓ TCS use (p = 0.024)	NA	Usual TCS as needed	Hon et al. [22]
Dermacare Atopic Lotionb,d	19 pts, 6 mo–3 y, mild–mod AD, no lesions	OL	BID 28 days	TEWL, EASI	None	14 d: ↓ TEWL (p = 0.035) forearm; ↓ TEWL (p = 0.061) cheek (trend) 28 d: NS; ↓ EASI (p = 0.002)	NA	No	De Lucas et al. [23]
Dr Hauschka Med Ice Plant Body Care Lotion and Intensive Ice Plant Creamb	38 pts, 2–4 y, eczema, predisposed to AD	Randomized, participant-blinded	Lotion to entire body except face; cream to face and forearms. BID, 16 weeks	Corneometry; TEWL for forehead, forearm, leg; SCORAD	Codex lotion and creamd	↑ Hydration at forearm and leg (wk 4 and 12); ↓ TEWL forearm, wk 12, leg, wk 4; ↓ SCORAD (p < 0.014)	↑ Hydration wk 16 vs. Codex (p < 0.038); ↓ TEWL (wk 16) forehead, p = 0.024; forearm, p = 0.039 vs. Codex; SCORAD NS difference	>3 days TSC dropout	Schario et al. [24]
Eucerin Eczema Relief Body Creamc	64 pts, 3 mo–12 y, mild–mod AD 26 pts, 3 mo–12 y, active lesions subgroup	OL	BID 2 wk to lower legs (full panel); BID 2 wk to active lesions and surrounding skin (subgroup)	Corneometry	None	↑ Hydration (p ≤ 0.001) full panel; ↑ hydration (p ≤ 0.001) in active lesion and surrounding skin (subgroup)	NA	No	Weber et al. [25]
Eucerin Eczema Relief Flare-up Treatmentc	29 pts, 3 mo–12 y, mild–mod AD, active flares	OL	BID 2 wk to active lesions and surrounding skin	Corneometry, ADSI	None	↑ Hydration (p ≤ 0.001) in active lesion and surrounding skin; ↓ ADSI (p < 0.001)	NA	No	Weber et al. [25]
Eucerin Soothing Lotionb	55 pts, 3 mo–14 y, mild–mod AD, active flares	RCT, DB, split-side	BID to half of active flare, HC to other half, 4 wk	SCORAD, TEWL	1% HC	↓ SCORAD both treatments (p < 0.001); ↓ TEWL (p = 0.03); HC TEWL NS	SCORAD NS vs. 1% HC; TEWL not performed	No	Wananukul et al. [26]
Skin barrier: Adult studies
Cetaphil Restoraderm Moisturizerc	30 pts, 18–55 y, AD history	RCT, evaluator-blinded	Nonlesional skin on forearm irritated with SDS 24 h then treated. TID, 5 d	TEWL, corneometry	1. ECC 2. PAI 3. Untreated	NR	1 and 2. No difference in ↓ TEWL or ↑ hydration vs. ECC or vs. PAI 3. ↓TEWL vs. untreated (p < 0.05) All ↑ hydration vs. untreated (p < 0.01)	NR	Simpson et al. [20]
Cetaphil Restoraderm Moisturizerc	20 pts, 18–65 y, controlled AD	RCT, investigator-blinded	BID to 1 lower leg; other untreated for 27 d	TEWL, corneometry	Untreated	NR	TEWL NS; change minor; ↑ hydration vs. untreated	NR	Simpson et al. [27]
Curel Moisture Creamb	40 pts, 7–37 y, mild–mod active AD	OL	BID 4 wk to all affected areas	SCORAD, TEWL, corneometry	None	↓ SCORAD (p < 0.001); ↑ TEWL (p = 0.1); ↑ Hydration (p < 0.001)	NA	TCS use documented	Seghers et al. [28]
Dermalex Eczemab	48 pts, 23–51 y, mild–mod AD	RCT, split-side	BID 6 wk to active lesions	SCORAD, TEWL, corneometry	1% HC	↓ SCORAD (p < 0.001); ↓ TEWL (p < 0.05); ↑ Hydration (p < 0.001)	NS differences in SCORAD, TEWL; ↑ hydration vs. HC (p = 0.018)	None	Koppes et al. [29]
Eucerin Eczema Relief Body Creamc	33 pts, > 18 y, mild–mod AD	OL	BID 2 wk to lower legs	Corneometer, TEWL	None	↑ Hydration (p ≤ 0.001); ↓ TEWL (p < 0.05)	NA	No	Weber et al. [30]
Eucerin Eczema Relief Flare-up Treatmentc	33 pts, > 18 y, mild–mod AD, active lesions	OL	BID 2 wk to active lesions	Corneometer, TEWL	None	↑ Hydration (p = 0.006); ↓ TEWL (p = 0.035) of active lesions	NA	No	Weber et al. [30]
Eucerin AtopiControl Acute Creamb	20 pts, 12–65 y, mild–mod AD, active lesions	DB, split-side	BID 7 days to forearms	TEWL, corneometry, SCORAD	1% HC	↓ TEWL (p < 0.01); ↑ Hydration (p < 0.05); ↓ SCORAD (p < 0.01)	NS differences between tx for TEWL, corneometry, or SCORAD	No	Angelova-Fischer et al. [31]
Kamedis CALM Eczema Therapy Creamc	20 pts, > 18 y, mild–severe AD, active lesions	OL	BID 3 wk	SCORAD, TEWL, corneometry	Untreated site	↓ SCORAD at d14 and d21 (p < 0.001); ↑ Hydration (p < 0.001); ↓ TEWL (p < 0.001)	TEWL and corneometry (p < 0.001) vs. untreated	No	Bomstein et al. [32]
Linola-F (Linoleic acid-moisturizer)b	20 pts, 2–45 y, mild–mod AD, active lesions	OL, RCT, split-body	2–3/d 4 wk	SCORAD, TEWL, corneometry	Eucerinum anhydricum ointment compounded with 5% urea	NR	NS differences in SCORAD, TEWL, hydration between tx; pH significantly ↑ Linola vs. Eucerinum	NR	Nasrollahi et al. [33]
Receutics Active Skin Repairc	25 pts, > 18 y, mild–mod AD	OL	TID 2 wk	Corneometry	None	↑ Hydration (p < 0.001)	NA	Oral treatments allowed	Draelos [34]
Suvex Sootheb	32 pts, 20–72 y, AD history	OL, split-body	BID 14 d to forearm; other untreated	TEWL, corneometry	Untreated	↓ TEWL (p < 0.01); ↑ Hydration (p < 0.01)	Numerically improved TEWL and hydration vs. untreated; statistical analysis NR	No	Wakeman [35]
Incidence of flares and time-to-flare studies
Atoderm Intensive creamc	123 pts, ≤ 7 y, mild–mod AD, active lesion	RCT	BID 6 mo	Time to flare	Vehicle		59 vs. 39 d (p < 0.00001); no. of flares NS between groups	TCS and calcineurin inhibitors	Gayraud et al. [36]
Aquaphor,c Cetaphilc Doublebase gel,d or Sunflower oilc	124 high-risk neonates aged > 3 wk	RCT	≥1 ×/day full body 6 mo	Incidence of flare	Untreated		22 vs. 43% flare (p < 0.05)		Simpson et al. [37]
Bepanthen SensiDailyb	108 pts, 2–49 mo, stabilized mild AD	RCT	BID 3 mo	SCORAD, flare	Stelatopia emollient cream	↓ SCORAD both treatments	SCORAD NS between groups. Time to flare: 47 vs. 50 d; incident flares: 4 vs. 14.5%	No	Stettler et al. [38]
Canoderm Cream 5%b	44 pts, 18–65 y, cleared AD	RCT	BID to designated areas, 22 wk	Time to relapse, TEWL at 3 wk	Untreated		>180 vs. 30 d median (p = 0.01); TEWL NS	Cosmetics and TCS allowed to other areas of body	Wirén et al. [39]
Canoderm Cream 5%b	172 pts, > 18 y, cleared AD	RCT	BID to designated areas, 6 mo	Time to relapse	Minidermd without glycerol		22 vs. 15 d (p = 0.0129)	No	Åkerström et al. [40]
Cetaphil Restoraderm lotion and washc	64 pts, 2–12 y, mild–mod AD, cleared	RCT, investigator-blinded	BID lotion + wash entire body, 12 wk	Time to flare (d)	Body wash alone		Time to flare: 62 vs. 89 d; 12 wk: 50 vs. 75% flared (p = 0.08)		Ma et al. [41]
Cetaphil Restoraderm moisturizerc	100 high-risk neonates aged > 3 wk	RCT	Daily to entire body, 12 mo	Incidence of AD (flare)	Emollient of choice, as needed		13.2 vs. 25.0% flared		McClanahan et al. [42]
Eucerin AtopiControl Lotionb	25 pts, 18–65 y, mild–mod AD, no active flares	DB, RCT, split-body	Bilateral BID treatment and V on forearms, 12 wk	Relapse, TEWL, hydration, SCORAD, itch	Vehicle	TEWL similar in nonlesional skin; higher in lesional	Relapse: 28.6 vs. 71.4% (p < 0.01); 60% decline in relapse; ΔTEWL > for V; ↓ SCORAD and ↓ itch vs. V (p < 0.001); ↑ hydration (p < 0.01)	No	Angelova-Fischer et al. [43]
Eucerin Eczema Relief Body Creamc	43 pts, 7 mo–12 y, history of AD, no flares	RCT	BID 6 mo for n = 23; n = 19 untreated	Time to flare	Untreated		Mean 55 vs. 22 d (p = 0.002); 21 vs. 65% flared (p = 0.006); > 180 d vs. 30 median	Mild cleanser for both bathing	Weber et al. [44]
Exomega Emollient Creamb	108 pts, 6 mo–6 y, mod AD, cleared	OL	BID 3 mo + QD TCS for flares	SCORAD, flares	None	↓ SCORAD (p < 0.0001); No. of flares decreased from 2.4 to 0.42/mo (p < 0.0001)	NA	Flares: QD fluticasone 0.05%	Mengeaud et al. [45]
Stelatopia emollient creamb	92 pts, 5 mo–5 y, mild–mod AD, active flares	RCT, observation-blinded	BID to entire body, 3 wk	SCORAD, flares	1% HC BID to affected areas	↓ SCORAD (p < 0.01) both groups; 93% saw decrease in no. of flares	SCORAD NS between groups; decrease in flares: 93 vs. 80% pts using 1% HC	Allowed	De Belilovsky et al. [46]

AD atopic dermatitis, ADSI Atopic Dermatitis Severity Index, BID twice daily, DB double-blind, EASI Eczema Area and Severity Index, ECC Eucerin Calming Cream, HC hydrocortisone, mo month(s), mod moderate, NA not applicable, NR not reported, NS not significant, OL open label, PAI Physiogel AI cream, pts patients, QD once daily, RCT randomized controlled trial, SCORAD Scoring Atopic Dermatitis, SDS sodium dodecyl sulfate, TCS topical corticosteroids, TEWL transepidermal water loss, TID three times daily, tx treatment, V vehicle, wk week(s), y year(s)

aAll patients had AD, severity, and flaring status listed if reported (EASI scores)

bNot marketed in the USA

cMarketed in the USA

dCan buy online in or have shipped to the USA

Flare studies indicated that daily moisturization significantly reduced the number of flares compared with untreated skin. A pooled analysis of six of the studies (n = 607) included in the Cochrane study, looking specifically at prevention of flares, demonstrated that daily moisturization significantly reduced the number of flares compared with untreated controls (p < 0.0006) [15].

Two studies investigated the ability of daily moisturization to proactively prevent flares in patients with AD. These randomized, 6-month studies investigating the effect of twice-daily moisturizer compared with no treatment demonstrated that both the US Eucerin Eczema Relief Body Cream and the Swedish Canoderm Cream significantly lengthened time to flare and reduced the total number of flares, in pediatric and adult populations, respectively [44, 39]. The median time to flare was > 180 days with daily moisturizer treatment in both studies, versus 28 and 30 days in the untreated groups of the pediatric and adult studies, respectively [44, 39]. Pooled analyses of these studies indicated that daily moisturization significantly reduced the risk of flare (p = 0.001) and the rate of flare by a factor of 3.74 (p = 0.0002) compared with untreated controls [15].

In addition to preventing flares in patients diagnosed with AD, proactive treatment of high-risk neonates reduced the development of AD [37]. This study was predicated on the knowledge that a family history of AD, allergic rhinitis, or asthma increases the likelihood of an infant developing AD. In this study, 124 neonates with a first-degree relative with one of these conditions were randomized to receive full body coverage (scalp excluded) of an emollient (Aquaphor Healing Ointment, 50% paraffin in white petrolatum, Cetaphil Cream, Doublebase Gel, or sunflower oil) daily, starting at or before 3 weeks of age. At 6 months, only 22% of neonates receiving daily emollient therapy developed AD versus 43% in the control group, corresponding to a significant risk reduction of 50% [37]. Several studies of proactive moisturization of high-risk infants support the effectiveness of primary prevention of AD [47], although another study by the original investigators showed a protective but nonsignificant effect of daily use of a therapeutic moisturizer (AD diagnosed in only 13.2 vs. 25.0% in the control group at 12 months), likely because the study was underpowered [42].

Many of the studies reviewed were not randomized controlled trials (RCTs). Large-scale RCTs are the gold standard for pharmaceutical approvals, but the high costs associated with these trials are impractical when testing nonprescription product formulations that will not be covered by insurance but need to be available to consumers at a reasonable cost.

Moreover, topical nonprescription formulations have multiple components that contribute to their efficacy, rendering “placebo-controlled” studies impossible. Consequently, most “controls” are an untreated group or an untreated side of a patient in the case of split-body studies. Although rare, a few vehicle-controlled studies exist [36, 43] that eliminate multiple key “active” ingredients and compare outcomes with the complete formulation.

Currently, there is no gold standard for nonprescription product testing. The endpoints chosen in this literature search—TEWL, corneometry, symptom relief—appear to be robust measures. Time to flare and number of flares versus untreated controls could also be considered objective and relevant measures. However, study design details such as sample size, length of study, controls, and blinding were not standardized. Moreover, pruritus is among the primary symptoms of AD, yet assessment measures for pruritus are not standardized and are frequently omitted from study designs.

Types of Moisturizers

Moisturizers come in many formulations, ranging from oils and ointments to lotions and gels. Moisturizers are not created with equal component ingredients; some can actually worsen skin function and even induce skin irritation [48, 49]. Traditionally, ointments and occlusives were thought to be the most beneficial for eczema because of their protective effects, whereas creams were assumed to provide better moisturization than lotions because of their greater viscosity. However, these premises are no longer true as modern technology has allowed the development of efficacious, more aesthetically pleasing formulations that improve compliance and therefore outcomes [50].

Moisturizers have evolved from providing basic barrier protection (occlusives) to hydrating care (humectant enriched) to products that address specific skin conditions (therapeutic).

Occlusives include ointments (mostly water-free lipid formulas) and basic water-in-oil creams and lotions (emulsions or suspensions of water into hydrophobic emollients and oils) that reduce TEWL and protect the skin against external irritants.

Humectant-enriched moisturizers include cream and lotion formulations of oil-in-water and water-in-oil emulsions as well as hydrogels. Incorporating humectant ingredients ranging from glycerin to natural moisturizing factor (NMF) components of the skin (e.g., urea, lactate, amino acids, pyrrolidone carboxylic acid, hyaluronic acid), these moisturizers hydrate the skin by attracting and binding water.

Therapeutic moisturizers are not restricted to any formulation type, as they are designed to address the specific symptoms of diseased skin. These formulations improve and support the skin barrier as well as hydration but also include ingredients that reduce inflammation or restore lipids, depending on the skin pathology being treated. Further, a true therapeutic moisturizer should be clinically evaluated and demonstrate efficacy for the respective conditions they are intended to treat [48].

Therapeutic moisturizers are formulated with ingredients that address the symptoms or contributory factors that may exacerbate the severity of the disease or condition (e.g., itch, inflammation, barrier disruption, ceramide deficiency). The formulation should have the physical properties that provide adequate absorption of ingredients and a pH of 4–5 to re-establish the normal physiological pH of skin. An aesthetically elegant product can potentially improve compliance.

Classifying Moisturizers

Understanding where therapeutic moisturizers for AD fit in among the plethora of topical agents can be complicated. The FDA classifies topical products as cosmetics, over-the-counter (OTC) drugs, prescription drugs, or prescription medical devices (Table 3). Cosmetic products are limited by the FDA to only claim effects on the appearance of the skin (per the US Federal Food and Cosmetic Act of 1938). Drugs are agents that have a pharmacologic action; prescription drugs require extensive clinical testing and approval by the FDA before being introduced to the market. OTC drugs must comply with their relevant OTC drug monograph, a guidance of acceptable ingredients and concentrations, disease indications, claims, dosing, and labeling. In contrast to prescription drugs, products conforming to existing OTC drug monographs can be marketed without FDA approval.

Table 3

US FDA categorization of topical products used in atopic dermatitis

Cosmetics (appearance or cleansing): available without prescription	Drugs (agents with pharmacologic action)		Medical devices (physically mediated effects): requires prescription
	OTC nonprescription drugs	Prescription drugs
FDA regulated, not FDA approved	FDA regulated, not FDA approved	FDA approval requires NDA with demonstration of safety and efficacy required	Premarket 501(k) submission requires demonstration of substantial equivalence to an existing barrier cream (limited clinical efficacy testing part of device application)
Limited to claim only effects on the appearance of the skin	Comply with FDA OTC drug monographs		Barrier cream products have physically (not chemically) mediated effects
No claims of effects on structure, function, or disease treatment allowed	For eczema, only products containing 0.007–2% colloidal oatmeal (OTC skin protectant) or 1% HC (OTC external analgesic) are allowed to make claims about effects on eczema symptoms

HC hydrocortisone, NDA new drug application, OTC over the counter

In order for any US moisturizer to be able to make claims of symptom relief for eczema, the FDA has designated only two ingredients as “allowed actives”: (1) under the FDA’s OTC External Analgesic monograph, hydrocortisone can claim use for the temporary relief of itching and inflammation due to eczema and (2) under the FDA’s OTC Skin Protectant monograph, colloidal oatmeal can claim to provide temporary skin protection and relief of minor skin irritations and itching due to eczema [51]. These effects have been previously established in the literature and thus approved by the FDA. If a product does not contain either hydrocortisone or colloidal oatmeal, nor comply with the regulations in the relevant OTC monographs, no claims can be made regarding eczema relief.

In the USA, AD therapeutic moisturizers are nonprescription and may be classified as either cosmetic formulations or OTC drug products; these products typically avoid ingredients that may exacerbate diseased skin, such as fragrances [2, 50].

Several prescription barrier creams (e.g., Atopiclair, EpiCeram) are indicated for AD. Categorized as class II medical devices, these require a premarket FDA 501(k) submission, whereby the device must demonstrate “substantial equivalence” to already approved medical devices. These products do not need to demonstrate safety and clinical efficacy through rigorous clinical trials mandated by the FDA new drug application process [3]. Studies of barrier creams have shown them to be safe and to reduce the incidence of flares [5, 52]; however, several comparative studies have shown no greater efficacy than achieved with nonprescription moisturizers [53, 54]. Notably, many of the ingredients included in barrier creams when first developed (e.g., ceramides, NMFs) are now included in nonprescription moisturizers formulated for the treatment of eczema [3]. Moreover, barrier creams are more expensive than nonprescription products [3, 53], and insurance coverage may be improbable.

Therapeutic Moisturizers for the Treatment of AD

For AD, therapeutic moisturizers need to provide essential barrier care (Table 4). Several AD therapeutic moisturizers have demonstrated their ability to decrease TEWL and increase skin hydration (e.g., Cetaphil Restoraderm moisturizer and wash, Eucerin Eczema Body Cream, Eucerin Flare-Up Treatment) and reduce the number of flares (e.g., Canoderm Cream, Eucerin Eczema Relief Body Cream, Eucerin AtopiControl Lotion) (see Table 2).

Table 4

The importance of essential skin barrier repair in atopic dermatitis

Strengthens the barrier that protects against environmental triggers (e.g., skin irritants, aeroallergens, dust mites, pet dander)

Decreases moisture loss that perpetuates damage and can provoke inflammatory processes

Promotes a healthy microbiome via induction of antimicrobial peptides

Maintains stratum corneum acidification, which protects against pathogens

Reduces recurrence of flares when used daily

Prevents onset of atopic dermatitis when applied early in life to at-risk children

Sometimes termed “emollient plus” [2], AD therapeutic moisturizers go beyond basic emollients to include ingredients that provide skin protection, essential lipids, and antipruritic, anti-inflammatory, and antioxidant properties to help counter the symptoms of AD (Table 5).

Table 5

Key ingredients in nonprescription therapeutic moisturizers for atopic dermatitis

Therapeutic properties	Examples of ingredients
Skin protectant	Colloidal oatmeala [51]
Antipruritic	Hydrocortisoneb, mentholc, pramoxine HClc, menthoxypropanediol [55, 56], colloidal oatmeala [51]
Anti-inflammatory	Licochalcone A [57], hydrocortisoneb, colloidal oatmeala [51]
Antioxidant	Glycyrrhetinic acid [58], licochalcone A [57]
Essential barrier lipids	Ceramides [59], plant oils rich in linoleic acid [60], urea (to upregulate ceramide production)
NMF	Lactic acid, amino acids, PCA, urea [61]
pH buffer	Acidic buffers optimizing pH between 4 and 5 (e.g., citric acid)

NMF natural moisturizing factor, OTC over the counter, PCA pyrrolidone carboxylic acid

aActive ingredient under the US FDA Skin Protectant OTC drug monograph allowed to claim use for eczema indication and the temporary relief of its symptoms

bActive ingredient under the US FDA External Analgesic OTC drug monograph, allowed to claim use for the temporary relief of itching and inflammation due to eczema

cActive ingredient under the US FDA External Analgesic OTC drug monograph, allowed to claim use for the immediate relief of itching due to minor skin irritations, inflammation, and rashes due to eczema

Colloidal oatmeal contains a mixture of various dermatologic active compounds that provide moisturizing, skin-protectant, anti-inflammatory, antioxidant, and antipruritic effects. The starches and β-D-glucans in oatmeal help to create an occlusive barrier that both moisturizes and relieves itch, whereas antioxidants such as avenanthramides, vitamin E, and ferulic acid have demonstrated anti-inflammatory activity [51].

Ceramides are important barrier lipids in preventing TEWL. Moisturizers may address ceramide deficiencies in AD by adding them to the formulation, by adding ingredients that can upregulate de novo ceramide production (e.g., urea [62, 63], niacinamide [64]), or by changing the physiologic milieu to support and promote ceramide production (e.g., lactic acid [62, 65]).

Maximizing Outcomes for Patients with AD

Healthcare providers can maximize patient outcomes by stressing the benefits of daily emollient therapy to their patients, particularly highlighting flare prevention. Evidence has consistently shown that daily application of a therapeutic moisturizer improves the skin barrier and reduces the number and frequency of flares. These outcomes can result in greater quality of life and potential cost benefits by reducing the number of lost days at work [66]. For neonates, those at high risk of developing AD can delay or even avoid AD by proactive treatment with a therapeutic moisturizer (primary prevention) [37].

Recommending clinically proven therapeutic moisturizers to patients is key to a successful therapeutic outcome. Instructions should stress that moisturizers should be applied liberally and daily—ideally twice. Recommendations should be based on formula composition and the strength of clinical data supporting the formulation [48]. Clinical demonstrations should include both objective measures of skin hydration and TEWL and validated clinical scales to assess symptom improvement. Product selection should also consider patients’ experience and preference [67, 68], as therapeutic efficacy can be provided in aesthetically pleasing, lighter formulations that can improve compliance.

Topical corticosteroids are generally recommended as the next step in the treatment of AD, particularly for the targeted treatment of flares. Topical steroid formulations may include penetration enhancers designed to enhance the delivery of active steroid to its target, which may weaken the barrier. Consequently, maintaining daily moisturization is important when topical steroids are added to the treatment regimen [50].

Limitations

This review does not attempt to assess the quality of the studies reviewed (extensively evaluated by van Zuuren et al. [15]) but rather presents a practical guide for the clinician of therapeutic moisturizers and the data and studies that support their use.

Minimal clinically important differences (MCIDs [69]) were not addressed in any of the cited publications or this review because of a lack of information on both thresholds for objective biophysical measures (TEWL and corneometry) and MCID evaluations for nonprescription interventions for patients with mild to moderate conditions. Instead, we took a positive statistical difference in TEWL, corneometry, and reduction of flare incidence as evidence of the product being beneficial to the patient.

Furthermore, we focused on the effects of the products on clinical and biophysical skin measures. It is beyond the scope of this review to classify the products as being occlusive, humectant-enriched, or therapeutic, as many of them may span several classes.

Conclusions

Therapeutic moisturizers should be used daily as the bedrock of AD management, underlying all additional treatments. Evidence has shown that, in many cases, reinforcing a back-to-basics approach with daily moisturization can be sufficient for the treatment of mild AD, strengthening the skin barrier and reducing the symptoms and outbreaks of AD. This review identified several proven and available consumer products that have been clinically tested using objective measures. Understanding what makes a moisturizer therapeutic, and how they differ from cosmetic products and prescription barrier creams, will help healthcare providers make informed choices to optimize outcomes for their patients. Healthcare provider recommendations on the right choice of moisturizers for the patient should be based on clinical evidence and patients’ preference and willingness to use. Twice-daily moisturization should be the mainstay of treatment for AD.

Daily moisturization is the bedrock of atopic dermatitis (AD) management, as recommended by all international guidelines.

Therapeutic moisturizers developed specifically for the treatment of AD demonstrate improved skin barrier and reduced incidence of flares in clinical trials.

Healthcare providers can help improve the skin condition of patients by informed recommendation of clinically proven, scientifically validated therapeutic nonprescription moisturizers and encouragement to use the product regularly.